REGN13089-M404-M2980
/ Regeneron
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 08, 2026
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
(clinicaltrials.gov)
- P1/2 | N=320 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals
New P1/2 trial • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Papillary Carcinoma • EGFR
1 to 1
Of
1
Go to page
1